Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03094897
Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics
Overview
The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.
Sponsor
Sichuan Provincial People's Hospital
Phase
Early Phase 1
Contacts
min Yang, PhD (CONTACT)
ymzfk@163.com
0510-88682783
chunjing Yu, PhD (PRINCIPAL_INVESTIGATOR)
chunjing Yu, PhD,MD (CONTACT)
ycj_wxd1978@163.com
0510-88682783
ClinicalTrials.gov
NCT03094897Drug / Compound
Al-NOTA-MATBBN
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- GRPR
Ligand Class: Peptides
Chelator: NOTA
Eligibility
Inclusion
- The patients have been diagnosed with cancer or suspected with cancer;
Exclusion
- Hypertensive patients with serious complications;
- Cardiac functional insufficiency;
- Hepatic and renal function insufficiency;
Share your feedback
Help us improve your experience